Sulagna Bhattacharya, Nanoscope Therapeutics CEO
March 30, 2023 11:43 AM EDT
R&D
Cell/Gene Tx

Nanoscope’s eye dis­ease gene ther­a­py shows mixed re­sults in PhII

Lei Lei Wu

News Reporter

Dal­las-based biotech Nanoscope Ther­a­peu­tics un­veiled Phase II re­sults on its gene ther­a­py for a rare eye dis­ease Thurs­day morn­ing.

In the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times